Although alterations in the p53 tumor suppressor gene are detected frequently in human breast cancers, mammary tumors are observed infrequently in p53 null mice. This has led to the suggestion that absence of p53 alone is not sucient for induction of mammary tumors. However, early death of p53 null mice from thymic lymphomas may obscure tumor phenotypes that would develop later. Therefore, p53
Introduction
Altered expression and mutation of the p53 tumor suppressor gene is observed frequently in human breast cancers (Elledge and Allred, 1994; Coles et al., 1992; Delmolino et al., 1993; Lehman et al., 1993) , suggesting that abrogation of p53 function is a pivotal event in the natural history of breast tumors. However, it has been dicult to establish whether loss of p53 function is an early or late event in tumor development. Biochemical and functional analysis of p53 has demonstrated its participation in regulation of the cell cycle, apoptosis in response to DNA damage, senescence, DNA repair and centrosome stability. Disruption of any of these pathways could contribute to development of breast cancers and it remains unclear which of these biochemical functions of p53 is dominant in ful®lling its tumor suppressor activity in breast tissue.
Many mammary tumor models have been developed to study the process of tumorigenesis in vivo, but most have proven to be of limited utility in analysing the role of p53. In mammary tumors induced by chemical carcinogens (DMBA or NMU) , the ras pathways are mutated preferentially and rarely result in altered expression or mutation of p53 (McKenzie et al., 1997; Qing et al., 1997; Kito et al., 1996; Kumar et al., 1990; Jerry et al., 1994) . Likewise, mammary tumors that arise from targeted overexpression of dominant-acting oncogenes do not appear to require disruption of the p53 pathway (Ritland et al., 1997) . Dominant-acting immortalizing viral genes have been used to disrupt p53 function in transgenic mice (Tzeng et al., 1993 (Tzeng et al., , 1998 . Although p53 function appears to be impaired in mice expressing SV40 large T-antigen, the phenotype is complicated by the disruption of dierentiation which is not observed in p53 null mice, indicating that additional pathways are disrupted by Tantigen. Overexpression of mdm2, a cellular antagonist of p53, also disrupted dierentiation of the mammary gland and resulted in late-appearing tumors, but acted through p53-independent pathways (Lundgren et al., 1997) .
Together, these data would appear to challenge the signi®cance of inactivation of p53 in the development of mammary tumors in rodents. Indeed, mammary tumors were observed infrequently in mice bearing homozygous deletions of the p53 gene (Donehower et al., 1992; Jacks et al., 1994) . DMBA-induced mammary tumors in p53 +/7 mice did not show loss of heterozygosity at the p53 locus (Jerry et al., 1994) . In contrast to the apparent lack of eect of altered p53 function alone, overexpression of ras or wnt-1 oncogenes in p53-de®cient mice led to more rapid development of mammary tumors which exhibited more aggressive features (Donehower et al., 1995; Hundley et al., 1997) . Overexpression of a dominantnegative mutant of p53 alone failed to exhibit a phenotype, but rendered the mammary gland more sensitive to tumor induction by chemical carcinogens and oncogenes (Li et al., 1997 (Li et al., , 1998 . In each of these cases, inactivation of p53 function led to increased aneuploidy in the resulting tumors. Mammary tumors in p53-de®cient mice bearing C3(1)-TAg transgene acquired more aggressive features and became metastatic (Maroulakou et al., 1997) . Therefore, abrogation of p53 function can be a critical event in tumor formation, even in the presence of oncogenes. Absence of p53 may also contribute to the development of genetic instability and increased metastatic potential.
These models demonstrate the potential importance of p53 status in mammary tumorigenesis, but it remains unclear whether absence of p53 alone increases susceptibility to mammary tumorigenesis. Therefore, the p53 null allele was transferred to the BALB/c genetic background as the BALB/c genetic background had been shown to be relatively susceptible to mammary tumorigenesis (Medina, 1974) . Transplantation of BALB/c-p53 null mammary epithelium into wild type BALB/c hosts allowed observation of the eects of absence of p53 in the mammary epithelium without complications associated with the eects of the p53 null allele on other tissues. Using this model, we demonstrated that absence of p53 renders the mammary epithelium exquisitely susceptible to tumor formation. Carcinogen treatment decreased signi®cantly the latency period for tumor appearance, but did not alter the ®nal tumor incidence in p53 null mammary transplants. Surprisingly, continuous hormonal stimulation alone was shown to dramatically increase the incidence of mammary tumors in p53 null transplants. The tumors were all adenocarcinomas and tended to be aneuploid. These data demonstrate that loss of p53 and hormonal stimulation synergize to create a potent tumorigenic environment. This animal model provides a valuable system with which to study p53-dependent mechanisms involved in mammary tumor development in the presence and absence of hormones.
Results
The eect of p53 null genotype on spontaneous mammary tumorigenesis and its interactions with carcinogenic stimuli were examined in this experiment. The eect of genotype was dramatic in the absence of carcinogen. No tumors developed in transplants of p53 wt mammary epithelium in either the untreated control treatment group or those groups subjected to hormonal stimulation (Pituitary-stimulated or Multiparous groups; Figure 1a , open symbols). In contrast tumors, were frequent in the transplants of p53 null mammary epithelium under all three treatment conditions ( Figure 1a , closed symbols). The overall tumor incidence in p53 null transplants was increased (P50.05) from 61.5% (16/26) in the untreated recipients to 100% (25/25) in recipients bearing pituitary isografts (Table 1) . Tumors arose more rapidly (P50.05) in the mice bearing pituitary-isografts (TE 50 =37 weeks) than in untreated mice (TE 50 =50 weeks). Tumor incidence in the multiparous group was 68% (19/28) with the TE 50 reached at 46 weeks.
Treatment with DMBA and chronic hormonal exposure were chosen as carcinogenic stimuli because both have been well characterized with respect to mammary carcinogenesis in mice (Medina, 1982 (Medina, , 1996 (Table 1; TE 50 for Pituitary-stimulated vs DMBA-Pits). The overall tumor frequency in the DMBA treated group was slightly less than that of the Pituitary-stimulated group presumably because of a shorter observation period (48 weeks vs 60 weeks). In contrast, the eect of chronic hormone exposure due to the presence of pituitary isografts resulted in increases in tumor incidence of 38.5% (Table 1 ; Untreated vs Pituitary-stimulated) and 30.5% (Table 1 ; DMBA vs DMBA+Pituitary-stimulated). These data reveal a surprising interaction between the absence of p53 and the biochemical eects of this hormone combination. Therefore, it appears that in the absence of the p53 gene product, this hormone combination is a more potent tumorigenic stimulus than the carcinogen DMBA.
All glands without tumors were collected at the end of the experiment, stained with hematoxylin, and examined as whole mounts under the dissecting microscope. All transplants from p53 wt mammary tissue presented normal duct or lobuloalveolar development depending on the absence or presence of pituitary isografts, respectively. A single exception was observed in one of the 25 non-tumor bearing glands from DMBA-treated mice in which a ®ne duct hyperplasia was present as a focal lesion. In contrast, six of 20 nontumor bearing glands with p53 null transplants exhibited ®ne duct hyperplasias and focal atypical duct hyperplasia, lesions that were observed in animals from both DMBA and untreated groups. Interestingly, no hyperplastic alveolar nodules, the common preneoplastic lesions occurring in MMTV-induced and spontaneous mammary tumors, were detected.
The histological appearance of tumors was uniform among the treatment groups. In general, the tumors were either moderate to poorly-dierentiated adenocarcinomas (Figure 2) . In some tumors, the nuclei were Tumor development in p53 null mammary transplants DJ Jerry et al extensively pleomorphic and the chromatin pattern was disorganized, indicating chromosomal abnormalities. For this reason, a subset of tumors was analysed for DNA content by¯ow cytometry. Rates of aneuploidy in the tumors from p53 null mammary outgrowths were surprisingly high among all treatment groups, ranging from 29% to 100% ( Table 2 ). Tumors that maintained normal ploidy had large S phase fractions (13 ± 20%). The S phase fractions did not dier dramatically among tumors from dierent treatment groups. Although the DMBA+Pituitary isograft treatment yielded the lowest frequency of aneuploidy, further analysis revealed an inverse relationship between ploidy and latency in tumors (Figure 3 ). All tumors (6/6) appearing prior to 26 weeks post-transplantation were euploid. Of these early appearing tumors, ®ve were derived from the DMBA+Pituitary-stimulated treatment group (which had the shortest overall latency) and one was derived from the untreated nulliparous group. Those tumors arising with a latency equal to or greater than 24 weeks post-transplantation were predominantly aneuploid (11/17) and were distributed null transplants, whereas hormonal stimulation by multiple pregnancies caused no greater tumor incidence than was observed for p53 null transplants in untreated hosts. This eect was evident only in p53 null transplants. (b) The tumorigenic eects of carcinogen treatment. The eect of DMBA, both alone and in combination with hormonal stimulation, were exacerbated in glands bearing p53
null transplants compared to those with p53 wt transplants
Tumor development in p53 null mammary transplants DJ Jerry et al among the treatment groups (two from DMBA+Pits; seven from DMBA alone; three from untreated nulliparous; ®ve from Pituitary-stimulated). These data demonstrate that aneuploidy is a signi®cant feature of mammary tumors arising from p53 null transplants, but was inversely related to tumor latency.
Discussion
Rodent models of breast cancer would ideally recapitulate the histological and molecular pathogenesis of human disease. There are numerous rodent models that recapitulate the major features of human disease. For example, the majority of human breast cancers develop from the terminal ductal-lobular units (Wellings et al., 1975) and this histological origin is re¯ected in both rat and murine mammary tumors (Russo et al., 1990; Cardi and Wellings, 1999) . Carcinogen-induced mammary tumors in both rats and mice have identi®ed critical periods of susceptibility during mammary gland development (Medina and Smith, 1999; Sivaraman et al., 1998) common to rodents as well as humans. Transplantable hyperplastic outgrowths provide a useful model of preneoplastic events and yielded much higher tumor frequencies than normal mammary glands following carcinogen treatment of hosts re¯ecting the enhanced risk associated with premalignant lesions (Medina, 1996; ) . Transgenic models have demonstrated the roles of speci®c pathways that, when altered, can induce mammary tumors (Amundadottir et al., 1995; Muller et al., 1998) . Although these models have provided valuable insights into mechanisms of tumorigenesis, the resulting mammary tumors from many of the models lack alterations in p53 that are commonly observed in human breast cancers. Aneuploidy is also an infrequent feature in many of the models. The frequent disruption of p53 function in human breast cancers suggests that this is a crucial event in the evolution of breast cancers. However, previous studies have not observed an increased susceptibility to mammary tumors in p53-de®cient mice (Donehower et al., 1992; Jacks et al., 1994; Jerry et al., 1994) . These experiments were limited by the use of mice with mixed genetic backgrounds (C57BL/66129Sv) which are more resistant to mammary tumorigenesis than BALB/c mice (Medina and Smith, 1999, submitted) . Second, the p53 null mice succumb to thymic lymphoma at very early ages (less than 21 weeks) (Jacks et al., 1994) and preclude the detection of mammary tumors that may arise later. Indeed, mammary hyperplasias are observed frequently in p53 null mice bearing the myc transgene (McCormack et al., 1998) . Therefore, the p53 null allele was backcrossed onto the BALB/c genetic background for nine generations in order to assess mammary tumorigenesis. These mice were suciently congenic to allow transplantation of the p53 null mammary epithelium into wild type BALB/c hosts. This approach allowed extended observation of the eects of the p53 null allele in mammary glands without complications associated with eects of the p53 null allele on other tissues. The transplantation of BALB/c-p53 null mammary epithelium provided clear and striking support for the notion that loss of p53 function is a major determinant of susceptibility to mammary tumorigenesis. This was evident in the absence of tumors in p53 wt mammary transplants in nulliparous hosts, whereas tumors were detected in 61.5% of the p53 null transplants in these same hosts. Surprisingly, continuous hormonal stimulation with pituitary isografts resulted in tumors in 100% of p53 null transplants, which is in stark contrast to the total absence of mammary tumors in p53 wt transplants. DMBA treatment did not aect the ®nal incidence of mammary tumors in p53 null epithelia, but did result in a decreased tumor latency ( Table 1) .
The relatively small eect of DMBA treatment on mammary tumor appearance, as compared to hormonal stimulation, was unexpected. Treatment with DMBA is known to cause adduct formation in genomic DNA which, if improperly repaired, would result in mutations (Ross and Nesnow, 1999) . In contrast, pituitary isografts provide a mitogenic stimulus similar to that encountered during midpregnancy (Christov et al., 1993) , and therefore, is thought to act to expand a population of cells bearing initiating mutations. Given the role of p53 in recognizing and ensuring DNA repair, the eect attributable to DMBA was surprisingly small. The dramatic eect of chronic hormonal stimulation on p53 null mammary epithelia suggests that, although DNA repair is impaired by the absence of p53, the major eect of p53 in mammary epithelial cells must involve other cellular events. Examples of alternate mechanisms leading to tumors in p53 null epithelia may include failure to ensure proper segregation of chromosomes or regulation of transcriptional activity of genes involved in redox cycling or angiogenesis.
The eects of hormone stimulation were assessed by two dierent procedures and yielded dierent results. Hormone stimulation by pituitary isografts provides continuous exposure to levels of prolactin, estrogen and progesterone similar to those attained in midpregnancy. This treatment results in continuous lobuloalveolar dierentiation of the mammary gland and caused a very high incidence of mammary tumors in the p53 null epithelial transplants. In contrast, hormonal stimulation by multiple parities provides sequential rounds of lobuloalveolar dierentiation, lactation and involution with consequent¯uxes in hormone levels. The latter procedure increased tumor incidence and decreased latency in p53 null mammary transplants, but only modestly. The two procedures do not provide equivalent hormonal and developmental stimuli to the mammary gland, and thus, are not necessarily comparable. Continuous hormone stimulation by pituitary isografts identi®ed a signi®cant synergism between hormones and p53 status on tumor development. The results also raise the question of which of the three hormones elevated by pituitary stimulation is critical for tumorigenesis and what cellular and molecular events in these mammary glands are normally regulated by wild type p53 protein. The number of tumors (expressed as %) that had abnormal DNA content based on FACS analysis. Disruption of p53 function has been associated with increased genetic instability in mammalian cells (Bouer et al., 1995; Fukasawa et al., 1996 Fukasawa et al., , 1997 Donehower et al., 1995) . With this result in mind, the incidence and degree of aneuploidy in mammary tumors was analysed by¯ow cytometry. Only p53 null mammary tumors were analysed because too few tumors were obtained from p53 wt transplants to provide meaningful results. Overall, 57% (13/23) of the mammary tumors from p53 null epithelial transplants exhibited aneuploidy. The euploid tumors were largely restricted to the DMBA treated groups where nine of the ten euploid tumors were observed. The relationship between latency and ploidy (Figure 3) suggests that tumors developing after a longer latency period are more likely to be aneuploid and that genetic instability is not an obligate feature of mammary pathogenesis associated with loss of p53 function. A similar conclusion was reached in analysis of mammary tumors arising in wnt-1/p53 null bitransgenic mice (Donehower et al., 1995) . The results reported herein, are the ®rst that we are aware of that evaluate p53-dependent aneuploidy in mammary tumors as a function of tumor latency. The results suggest that the absence of the p53 gene is aecting multiple cellular events and that the mechanisms generating aneuploidy are aecting cells over a long time period and are not necessary for tumor formation.
In summary, transplantation of p53 null mammary epithelium oers a versatile model system in which to study the eects of the p53 pathway on tumorigenesis. The results demonstrate that absence of p53 renders the mammary epithelium highly susceptible to tumor development. The dramatic eects of hormonal stimulation on tumor incidence in p53 null mammary transplants suggest that p53 plays a pivotal role in regulating hormone-induced molecular processes.
Materials and methods

Animals
The BALB/c-p53 null mice were derived by backcrossing the p53 null allele (Jacks et al., 1994) onto the BALB/c genetic background as described previously . Tissues for transplantation were obtained from mice at the 9th backcross generation. Procedures for transplantation of mammary epithelium into cleared mammary fat pads has been described previously (Medina, 1973 (Medina, , 1996 . In these experiments, 21 ± 24-day-old BALB/c females were used as transplant recipients. The endogenous mammary epithelium was surgically removed from the 4th inguinal glands to provide a cleared mammary fat pad. Single ducts were dissected from mammary glands of 8 ± 10-week-old BALB/cp53 null and wild type BALB/c females and transplanted into the cleared mammary fat pads of recipients. Both p53 null and p53 wt mammary ducts were transplanted into contralateral glands of each recipient to ensure an identical host environment. Twenty-eight to thirty mice bearing transplants were prepared for each treatment group. One group of mice bearing transplants were not subjected to further manipulations to provide the untreated control group. The pituitarystimulated group was prepared by implanting pituitary isografts under the kidney capsule at 5 weeks of age. The Multiparous treatment group was subjected to 3 ± 5 cycles of pregnancy, lactation (10 days) and involution (10 days). The DMBA alone treatment group received 1 mg of 7,12-dimethylbenz(a)anthracene in oil by gavage four times at weekly intervals beginning at 8 weeks of age. The DMBA+pituitary isograft group received pituitary transplants at 5 weeks followed by 1 mg DMBA by gavage two times at weekly intervals beginning at 8 weeks of age. The two groups receiving DMBA were monitored weekly for tumors for up to 48 weeks. The remaining treatment groups were monitored for up to 60 weeks. In the DMBA treated groups, two mice each were lost due to treatment. A decreased number of successful takes was observed for the p53 null transplants (125/141=88%) compared to the p53 wt transplants (139/142=98%).
Histological procedures
Mammary tumors were removed surgically and fragments were ®xed in 10% neutral buered formalin, then embedded in paran. Five micron sections were stained with hematoxylin and eosin for histopathological examination.
Tissues that did not form tumors during the observation period were removed after 48 weeks (DMBA and DMBA+pituitary isograft treatments) or 60 weeks (untreated, pituitary-stimulation, and multiparous treatments). These tissues were ®xed, defatted, then stained with hematoxylin (Medina, 1973) to allow examination of the entire gland for the presence of outgrowths and focal tumors. Wholemounts in which epithelium was absent represented unsuccessful transplants and were removed from the analyses.
Analysis of aneuploidy
Flow cytometry was performed as described previously (Li et al., 1998) . Cell suspensions were obtained by pepsin digestion of four to ®ve paran sections (50 mm each). The suspension was ®ltered, then stained with propidium iodide. The sample was analysed on a FACScan¯ow cytometer and 20 000 events were collected from each sample. DNA histograms were produced using ModFit LT software (Verity Software House, Topsham, ME, USA).
Statistical analysis
The tumor-free survival data were analysed using PROPHET 5.0 (BBN Systems and Technologies). Dierences among survival functions were analysed using the Mantel-Cox test. The dierences in tumor incidences were determined by the chi square procedure (Peto, 1974) . Dierences were considered statistically signi®cant if P50.05.
